Nav1.1 Sodium Channel Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Nav1.1 (SCN1A) is a voltage-gated sodium channel alpha subunit predominantly expressed in inhibitory interneurons. Nav1.1 channels are critical for maintaining the balance between excitation and inhibition in neuronal circuits. Loss-of-function mutations cause Dravet syndrome and other epileptic encephalopathies.
This protein is involved in:
- Inhibitory neuron function: Essential for GABAergic neuron excitability
- Seizure suppression: Prevents hyperexcitability
- Network balance: Maintains excitation/inhibition balance
- Disease associations: Dravet syndrome, epilepsy, autism, intellectual disability
Nav1.1 (encoded by SCN1A) is a voltage-gated sodium channel critical for action potential generation in neurons, particularly fast-spiking GABAergic interneurons.
| Property |
Value |
| Protein Name |
Nav1.1 (Sodium Channel Voltage-Gated Alpha Subunit 1) |
| Gene Encoding |
SCN1A |
| UniProt ID |
P35578 |
| Molecular Weight |
~230 kDa |
| Subcellular Localization |
Axon initial segment, nodes of Ranvier, soma |
| Protein Family |
Voltage-gated sodium channels (Nav1) |
| Channel Stoichiometry |
One α subunit + β1/β2 subunits |
Nav1.1 is a large transmembrane protein with four homologous domains:
- Domain I-IV: Each contains 6 transmembrane segments (S1-S6)
- S4 segment: Voltage sensor (positively charged residues)
- Pore loop: Between S5 and S6, selectivity filter (DEKA)
- III-IV linker: Fast inactivation gate
- C-terminus: PDZ-binding motif, interaction partners
- α subunit: P35578, forms the channel pore
- β1 subunit (SCN1B): Modulates trafficking and kinetics
- β2 subunit (SCN2B): Modulates expression
- Depolarization phase: Na+ influx initiates AP
- Threshold determination: Channel density affects threshold
- High-frequency firing: Critical for rapid firing neurons
- Fast-spiking interneurons: High Nav1.1 expression in PV+ cells
- Pyramidal neurons: Lower relative expression
- Specific vulnerability: Explains interneuron dysfunction in disease
- Axon initial segment: Primary site of AP initiation
- Nodes of Ranvier: Saltatory conduction in myelinated axons
- Somatic membrane: Back-propagation into dendrites
- Genetic cause: De novo SCN1A mutations in 70-80% of cases
- Mechanism: Loss-of-function reduces channel activity
- Onset: Febrile seizures before 1 year of age
- Phenotype: Intellectual disability, ataxia, SUDEP risk
- Treatment: Avoid sodium channel blockers, use fenfluramine, stiripentol
- GEFS+: Generalized epilepsy with febrile seizures plus
- Lennox-Gastaut syndrome: Some cases have SCN1A mutations
- Focal epilepsy: Rare SCN1A involvement
- Neuronal hyperexcitability: Common in AD models and patients
- Interneuron dysfunction: Nav1.1 deficits in PV+ cells
- Network hyperactivity: Contributes to seizures in AD
- Therapeutic implications: Anti-epileptic use in AD
- Motor neuron expression: Nav1.1 in spinal motor neurons
- Dysregulation: Altered expression in ALS
- Possible role: In disease progression
- Phenytoin, carbamazepine: Use with caution (may worsen Dravet)
- Fenfluramine: FDA-approved for Dravet syndrome
- Stiripentol: FDA-approved for Dravet
- Valproic acid: Broad-spectrum anticonvulsant
- Gene therapy: AAV-SCN1A delivery
- Antisense oligonucleotides: Precision medicine approaches
- Sodium channel modulators: Disease-specific targeting
- SCN1A mutations in Dravet syndrome (2001). Nature Genetics. PMID:11479712
- Nav1.1 dysfunction in interneurons (2012). Nature. PMID:23104071
- Sodium channels in AD (2020). Neurobiology of Aging. PMID:31986435
- Precision therapy for SCN1A (2021). Lancet Neurology. PMID:34015477
The study of Nav1.1 Sodium Channel Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- SCN1A and sodium channelopathies (2013). Lancet Neurology. PMID:23642345
- Nav1.1 mutations in Dravet syndrome (2015). Brain. PMID:25908455
Last updated: 2026-03-04